1. Get more info on this report!
World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline
Analysis of the Top 50 Companies)
July 1, 2010
What Will The Pharmaceutical Market Look Like in the Next Five Years?
In this report, Kalorama has analyzed the late stage R&D pipeline of the 50 top
companies in pharmaceuticals -- the companies that produce the lion's share of industry
revenues. While the report looks at the entire pipeline to 2015, a key focus of the report
is the increasing role of biopharmaceutical products. The growing interest in
biotechnology development has transitioned the pharmaceutical industry to
biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and
Novartis have been unable to ignore the benefits of investing in biotechnology and have
focused on a pipeline in this direction through strategic acquisitions and partnerships
with biotech companies and/or through their own in-house research efforts.
This Kalorama Information market research report, The World Pharmaceutical and
Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50
Companies) captures these trends, extracting sales for all pharmaceutical and
biopharmaceutical products (excluding prophylactic vaccines) and providing estimates
and forecasts of the world biopharma market.
Among the top companies in biopharmaceuticals are, not surprisingly, the same names
that have dominated pharmaceuticals for years - Pfizer, Merck and Novartis. These
companies have been unable to ignore the benefits of investing in biotechnology and
have focused on a pipeline in this direction through strategic acquisitions and
partnerships with biotech companies and/or through their own in-house research efforts.
Specialist companies such as Amgen and Genzyme, now competing with a growing
number of companies. The result of all interest in biological solutions to major diseases?
In creased activity in the research and development departments of major
pharmaceutical companies in recent years, activity that we believe will have near-term
market impact.
Key Issues and Trends in the Industry

2. Issues and Trends discussed in this report include:
Biotechnology Drug Development
Orphan Drugs
Fast Track Drug Status
Other Accelerated Methods for Drug Approval
Pharmaceutical Regulatory Exclusivity
Biosimilar Development
Aging Populations
Mergers, Acquisitions, and Collaborations
Contributors to R&D Success
R&D Spending Trends
The Role of Contract Research Organizations
Sustainability in a Changing Pharmaceutical Industry
Also, despite an in-depth interview process and complete review of company financials,
some variation in company rankings is possible. This is more likely with privately held
companies or companies where prescription pharmaceutical and biopharmaceutical
sales are not discussed.
In this comprehensive look a the pipeline of major companies, Kalorama Information
presents an accurate picture of the marketplace today, including
Market Estimates by Major Drug Category, including:
o Cardiovascular/Blood
o Neurotherapeutics
o Infection
o Oncology
o Respiratory/Inflammatory
o Gastrointestinal
o Other
Discussion of Marketplace Trends
Pipeline Analysis of Major Pharmacos
Detailed Company Profiles
Comparison of Market at Current Growth Versus Impact of Late-Stage
Products
Biopharmaceutical Market Breakdown
Best-Selling Biopharmaceutical Products
Regulatory Activity and Market Impact
Kalorama Information's market research into this topic is based on review of
government filings and company literature, but also interviews with executives and
experts, and the perspective of an analyst who has authored scores of reports in this
industry.
Late Stage Product Development of the Top 50 Companies

3. 50 top companies make up over 90% of the world biopharmaceutical market; The top
three companies have nearly a quarter of global sales in 2009.
Kalorama looks at each key player's late-stage pipeline in detail. The top 50 companies
discussed in this report include:
Abbott
Actelion
Alcon, Inc.
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene Corp.
Cephalon
Chugai Pharmaceutical
CSL
Daiichi Sankyo
Dainippon
Eisai
Eli Lilly & Co.
Endo
Forest
Genzyme
Gilead Sciences
GlaxoSmithKline
Hospira
Johnson & Johnson
Lundbeck
Menarini
Merck
Merck KGaA
Mitsubishi Tanabe Pharma
Mylan
Novartis
Novo Nordisk
Nycomed
Ono Pharmaceutical Co.
Otsuka Pharmaceutical
Pfizer
Procter & Gamble

4. Purdue Pharma
Roche
Sanofi-Aventis
Servier
Shionogi
Shire
Takeda
TEVA
UCB
Watson
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Potential Market Opportunity
Issues and Trends Affecting Market
Leading Companies
CHAPTER TWO: INTRODUCTION
Global Pharmaceutical Market
Pharmaceutical Research & Development Overview
o Clinical Trial Costs
CHAPTER THREE: ISSUES AND TRENDS
Biotechnology Drug Development
Orphan Drugs
Fast Track Drug Status
Other Accelerated Methods for Drug Approval
Pharmaceutical Regulatory Exclusivity
Pediatric Extensions
Biopharmaceutical Industry—Biosimilar (Biogeneric) Development and
Exclusivity Legislation
Aging Population
Mergers, Acquisitions, and Collaborations
Contributors To R&D Success
R&D Spending
The Role of Contract Research Organizations
Sustainability in a changing Pharmaceutical Industry

5. CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS
Introduction
Pfizer, Inc./Wyeth (merged in 2009)
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
Merck & Co., Inc.
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
Novartis AG
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
Roche Ltd.
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
Sanofi-Aventis
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
AstraZeneca plc
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
GlaxoSmithKline plc
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
Johnson & Johnson
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
Eli Lilly & Company
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
Bristol-Myers Squibb Company
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
Abbott Laboratories
o Overview
o Financial Performance and Investments

6. o Late Stage Pipeline
Takeda Pharmaceutical Co., Ltd.
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
Bayer AG
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
Amgen, Inc.
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
Boehringer Ingelheim GmbH
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
TEVA Pharmaceutical Industries, Ltd.
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
Astellas
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
Daiichi Sankyo
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
Novo Nordisk
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
Eisai
o Overview
o Financial Performance and Investments
o Late Stage Pipeline
CHAPTER FIVE: COMPANIES OF INTEREST
Introduction
Otsuka
o Late Stage Pipeline
Merck KGaA
o Late Stage Pipeline

7. Gilead Sciences
Late Stage Pipeline
Mylan
o Pipeline
Baxter International
o Late Stage Pipeline
Chugai Pharmaceutical Company, Ltd.
o Late Stage Pipeline
Mitsubishi Tanabe
o Late Stage Pipeline
Servier, Les Laboratories
o Pipeline
UCB SA
o Late Stage Pipeline
Allergan
o Late Stage Pipeline
Forest Laboratories
o Late Stage Pipeline
Nycomed International
o Late Stage Pipeline
Genzyme Corporation
o Late Stage Pipeline
Biogen Idec
o Late Stage Pipeline
Hospira
o Late Stage Pipeline
Watson
o Pipeline
CSL Limited
o Late Stage Pipeline
Alcon
o Late Stage Pipeline
Shire
o Late Stage Pipeline
Celgene Corporation
o Late Stage Pipeline
Lundbeck
o Late Stage Pipeline
Shionogi & Co., Ltd.
o Late Stage Pipeline
Menarini Group
o Late Stage Pipeline
Dainippon Sumitomo Pharma, Co., Ltd.
o Late Stage Pipeline

8. Cephalon
o Late Stage Pipeline
Actelion
o Late Stage Pipeline
Procter & Gamble
Endo Pharmaceuticals
o Late Stage Pipeline
Ono Pharmaceutical Co.
o Late Stage Pipeline
Purdue Pharma
o Late Stage Pipeline
CHAPTER SIX: MARKET FORECAST
Overview
Company Analysis
Pipeline Snapshot: Top 50 Companies
Current Market Value
Market Forecast
CHAPTER SEVEN: BIOPHARMACEUTICAL MARKET
Biopharmaceutical Companies
Biopharmaceutical Market Forecast APPENDIX: LIST OF COMPANIES
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: Global Pharmaceutical Market Research and Development Impact by
Therapeutic Segment, 2015—based on late stage development projects
evaluated ($ in billions)
Figure 1-1: Global Pharmaceutical Market Research and Development Impact by
Therapeutic Segment, 2015—based on late stage development projects
evaluated
CHAPTER TWO: INTRODUCTION
Table 2-1: Phases of Clinical Drug Development
Table 2-2: Components of a Clinical Trial
CHAPTER THREE: ISSUES AND TRENDS
Table 3-1: International Population Trend Age 65+
Figure 3-1: International Population Trend Age 65+
Table 3-2: United States Population Trend Age 65+
Figure 3-2: International Population Trend Age 65+

9. Table 3-3: Recent Pharmaceutical Business Mergers and Acquisitions
Table 3-4: Pharmaceutical/Biopharmaceutical R&D Statistics
Figure 3-3: Drug Development Cost Progression
Table 3-5: Total Industry R&D Spending 2004-2009
Figure 3-4: Total Industry R&D Spending 2004-2009
CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS
Table 4-1: Top Biopharmaceutical Companies, 1-20 by 2009 Sales (millions)
Table 4-2: Pfizer’s Total Company Revenue and R&D Spending 2007-2009
(Millions)
Figure 4-1: Pfizer’s Total Company Revenue and R&D Spending 2007-2009
(Millions)
Table 4-3: Pfizer’s Late Stage Product Pipeline
Figure 4-2: Pfizer’s Late Stage Product Pipeline by Therapeutic Area
Table 4-4: Merck’s* Total Company Revenue and R&D Spending 2007-2009
(Millions)
Figure 4-3: Merck’s* Total Company Revenue and R&D Spending 2007-2009
(Millions)
Table 4-5: Merck & Co.’s Late Stage Product Pipeline
Figure 4-4: Merck’s Late Stage Product Pipeline by Therapeutic Area
Table 4-6: Novartis’ Total Company Revenue and R&D Spending 2007-2009
(Millions)
Figure 4-5: Novartis’ Total Company Revenue and R&D Spending 2007-2009
(Millions)
Table 4-7: Novartis’ Late Stage Product Pipeline
Figure 4-6: Novartis’ Late Stage Product Pipeline by Therapeutic Area
Table 4-8: Roche’s Total Company Revenue and R&D Spending 2007-2009
(Millions)
Figure 4-7: Roche’s Total Company Revenue and R&D Spending 2007-2009
(Millions)
Table 4-9: Roche’s Late Stage Product Pipeline
Figure 4-8: Roche’s Late Stage Product Pipeline by Therapeutic Area
Table 4-10: Sanofi-Aventis’ Total Company Revenue and R&D Spending 2007-
2009 (Millions)
Figure 4-9: Sanofi-Aventis’ Total Company Revenue and R&D Spending 2007-
2009 (Millions)
Table 4-11: Sanofi-Aventis’ Late Stage Product Pipeline
Figure 4-10: Sanofi Aventis’ Late Stage Product Pipeline by Therapeutic Area
Table 4-12: AstraZeneca’s Total Company Revenue and R&D Spending 2007-
2009 (Millions)
Figure 4-11: AstraZeneca’s Total Company Revenue and R&D Spending 2007-
2009 (Millions)
Table 4-13: AstraZeneca’s Late Stage Product Pipeline
Figure 4-12: AstraZeneca’ Late Stage Product Pipeline by Therapeutic Area

10. Table 4-14: GlaxoSmithKline’s Total Company Revenue and R&D Spending
2007-2009 (Millions)
Figure 4-13: GlaxoSmithKline’s Total Company Revenue and R&D Spending
2007-2009 (Millions)
Table 4-15: GlaxoSmithKline’s Late Stage Product Pipeline
Figure 4-14: GlaxoSmithKline’s Late Stage Product Pipeline by Therapeutic Area
Table 4-16: Johnson & Johnson’s Total Company Revenue and R&D Spending
2007-2009 (Millions)
Figure 4-15: Johnson & Johnson’s Total Company Revenue and R&D Spending
2007-2009 (Millions)
Table 4-17: Johnson & Johnson’s Late Stage Product Pipeline
Figure 4-16: Johnson & Johnson’s Late Stage Product Pipeline by Therapeutic
Area
Table 4-18: Eli Lilly’s Total Company Revenue and R&D Spending 2007-2009
(Millions)
Figure 4-17: Eli Lilly’s Total Company Revenue and R&D Spending 2007-2009
Table 4-19: Eli Lilly’s Late Stage Product Pipeline
Figure 4-18: Eli Lilly & Co.’s Late Stage Product Pipeline by Therapeutic Area
Table 4-20: Bristol-Myers Squibb’s Total Company Revenue and R&D Spending
2007-2009 (Millions)
Figure 4-19: Bristol-Myers Squibb’s Total Company Revenue and R&D Spending
2007-2009 (Millions)
Table 4-21: Bristol-Myers Squibb’s Late Stage Product Pipeline
Figure 4-20: Bristol-Myers’ Late Stage Product Pipeline by Therapeutic Area
Table 4-22: Abbott’s Total Company Revenue and R&D Spending 2007-2009
(Millions)
Figure 4-21: Abbott’s Total Company Revenue and R&D Spending 2007-2009
(Millions)
Table 4-23: Abbott’s Late Stage Product Pipeline
Figure 4-22: Abbott’s Late Stage Product Pipeline by Therapeutic Area
Table 4-24: Takeda’s Total Company Revenue* and R&D Spending 2007-2009
(Millions)
Figure 4-23: Takeda’s Total Company Revenue and R&D Spending 2007-2009
(Millions)
Table 4-25: Takeda Pharmaceutical’s Late Stage Product Pipeline
Figure 4-24: Takeda Pharmaceutical’s Late Stage Product Pipeline by
Therapeutic Area
Table 4-26: Bayer’s Total Company Revenue and R&D Spending 2007-2009
(Millions)
Figure 4-25: Bayer’s Total Company Revenue and R&D Spending 2007-2009
(Millions)
Table 4-27: Bayer’s Late Stage Product Pipeline
Figure 4-26: Bayers’ Late Stage Product Pipeline by Therapeutic Area
Table 4-28: Amgen’s Total Company Revenue and R&D Spending 2007-2009
(Millions) Figure 4-27: Amgen’s Total Company Revenue and R&D Spending
2007-2009 (Millions)

11. Table 4-29: Amgen’s Late Stage Product Pipeline
Figure 4-28: Amgen’s Late Stage Product Pipeline by Therapeutic Area
Table 4-30: Boehringer Ingelheim’s Total Company Revenue and R&D Spending
2007-2009 (Millions)
Figure 4-29: Boehringer Ingelheim’s Total Company Revenue and R&D
Spending 2007-2009 (Millions)
Table 4-31: Boehringer Ingelheim’s Late Stage Product Pipeline
Figure 4-30: Boehringer Ingelheim’s Late Stage Product Pipeline by Therapeutic
Area
Table 4-32: TEVA’s Total Company Revenue and R&D Spending 2007-2009
(Millions)
Figure 4-31: TEVA’s Total Company Revenue and R&D Spending 2007-2009
(Millions)
Table 4-33: TEVA’s Late Stage Product Pipeline Figure 4-32: TEVA’s Late Stage
Product Pipeline by Therapeutic Area
Table 4-34: Astellas’ Total Company Revenue and R&D Spending 2007-2009
(millions)
Figure 4-33: Astellas’ Total Company Revenue and R&D Spending 2007-2009
(millions)
Table 4-35: Astellas’ Late Stage Product Pipeline
Figure 4-34: Astellas’ Late Stage Product Pipeline by Therapeutic Area
Table 4-36: Daiichi Sankyo’s Total Company Revenue and R&D Spending 2007-
2009 (millions)
Figure 4-35: Daiichi Sankyo’s Total Company Revenue and R&D Spending
2007-2009 (millions)
Table 4-37: Daiichi Sankyo’s Late Stage Product Pipeline
Figure 4-36: Daiichi Sankyo’s Late Stage Product Pipeline by Therapeutic Area
Table 4-38: Novo Nordisk’s Total Company Revenue and R&D Spending 2007-
2009 (millions)
Figure 4-37: Novo Nordisk’s Total Company Revenue and R&D Spending 2007-
2009 (millions)
Table 4-39: Novo Nordisk’s Late Stage Product Pipeline
Figure 4-38: Novo Nordisk’s Late Stage Product Pipeline by Therapeutic Area
Table 4-40: Eisai’s Total Company Revenue and R&D Spending 2007-2009
(Thousands)
Figure 4-39: Eisai’s Total Company Revenue and R&D Spending 2007-2009
Table 4-41: Eisai’s Late Stage Product Pipeline
Figure 4-40: Eisai’s Late Stage Product Pipeline by Therapeutic Area
CHAPTER FIVE: COMPANIES OF INTEREST
Table 5-1: Top Biopharmaceutical Companies, 21-50 by 2009 Sales
Table 5-2: Otsuka Pharmaceutical’s Late Stage Product Pipeline
Figure 5-1: Otsuka Pharmaceutical’s Late Stage Product Pipeline by Therapeutic
Area
Table 5-3: Merck KGaA’s Late Stage Product Pipeline

12. Figure 5-2: Merck KGaA’s Late Stage Product Pipeline by Therapeutic Area
Table 5-4: Gilead Sciences’ Late Stage Product Pipeline
Figure 5-3: Gilead Sciences’ Late Stage Product Pipeline by Therapeutic Area
Table 5-5: Baxter International’s Late Stage Product Pipeline
Figure 5-4: Baxter International’s Late Stage Product Pipeline by Therapeutic
Area
Table 5-6: Chugai Pharmaceutical’s Late Stage Product Pipeline
Figure 5-5: Chugai’s Late Stage Product Pipeline by Therapeutic Area
Table 5-7: Mitsubishi Tanabe’s Late Stage Product Pipeline
Figure 5-6: Mitsubishi Tanabe’s Late Stage Product Pipeline by Therapeutic Area
Table 5-8: UCB Pharma’s Late Stage Product Pipeline
Figure 5-7: UCB’s Late Stage Product Pipeline by Therapeutic Area
Table 5-9: Allergan’s Late Stage Product Pipeline
Figure 5-8: Allergan’s Late Stage Product Pipeline by Therapeutic Area
Table 5-10: Forest Laboratories’ Late Stage Product Pipeline
Figure 5-9: Forest Laboratories’ Late Stage Product Pipeline by Therapeutic Area
Table 5-11: Nycomed’s Late Stage Product Pipeline
Figure 5-10: Nycomed’s Late Stage Product Pipeline by Therapeutic Area
Table 5-12: Genzyme’s Late Stage Product Pipeline
Figure 5-11: Genzyme’s Late Stage Product Pipeline by Therapeutic Area
Table 5-13: Biogen Idec’s Late Stage Product Pipeline
Figure 5-12: Biogen Idec’s Late Stage Product Pipeline by Therapeutic Area
Table 5-14: Hospira’s Late Stage Product Pipeline
Figure 5-13: Hospira’s Late Stage Product Pipeline by Therapeutic Area
Table 5-15: CSL’s Late Stage Product Pipeline
Figure 5-14: CSL’s Late Stage Product Pipeline by Therapeutic Area
Table 5-16: Alcon’s Late Stage Product Pipeline
Figure 5-15: Alcon’s Late Stage Product Pipeline by Therapeutic Area
Table 5-17: Shire’s Late Stage Product Pipeline
Figure 5-16: Shire’s Late Stage Product Pipeline by Therapeutic Area
Table 5-18: Celgene’s Late Stage Product Pipeline
Figure 5-17: Celgene’s Late Stage Product Pipeline by Therapeutic Area
Table 5-19: Lundbeck’s Late Stage Product Pipeline
Figure 5-18: Lundbeck’s Late Stage Product Pipeline by Therapeutic Area
Table 5-20: Shionogi’s Late Stage Product Pipeline
Figure 5-19: Shionogi’s Late Stage Product Pipeline by Therapeutic Area
Table 5-21: Menarini’s Late Stage Product Pipeline
Figure 5-20: Menarini’s Late Stage Product Pipeline by Therapeutic Area
Table 5-22: Dainippon Sumitomo’s Late Stage Product Pipeline
Figure 5-21: Dainippon Sumitomo’s Late Stage Product Pipeline by Therapeutic
Area
Table 5-23: Cephalon’s Late Stage Product Pipeline
Figure 5-22: Cephalon’s Late Stage Product Pipeline by Therapeutic Area
Table 5-24: Actelion’s Late Stage Product Pipeline
Figure 5-23: Actelion’s Late Stage Product Pipeline by Therapeutic Area
Table 5-25: Endo Pharmaceutical’s Late Stage Product Pipeline

13. Figure 5-24: Endo Pharmaceutical’s Late Stage Product Pipeline by Therapeutic
Area
Table 5-26: Ono Pharmaceutical’s Late Stage Product Pipeline
Figure 5-25: Ono Pharmaceutical’s Late Stage Product Pipeline by Therapeutic
Area
Table 5-27: Purdue Pharma’s Late Stage Product Pipeline
Figure 5-26: Purdue Pharma’s Late Stage Product Pipeline by Therapeutic Area
CHAPTER SIX: MARKET FORECAST
Table 6-1: Top Pharmaceutical Companies, 1-50 by 2009 Sales (millions)
Table 6-2: Company Pipelines by Total Late Stage Development Projects (Top
20 Companies by Revenues)
Figure 6-1: Company Pipelines by Total Late Stage Development Projects (Top
20 Companies by Revenues)
Table 6-3: Company Pipelines by Total Late Stage Development Projects
(Companies 21-50 by Revenues)
Figure 6-2: Company Pipelines by Total Late Stage Development Projects
(Companies 21-50 by Revenues)
Table 6-4: Global Pharmaceutical Market Value by Therapeutic Segment, 2005-
2010 ($ in billions)
Figure 6-3: Global Pharmaceutical Market Value by Therapeutic Segment 2005-
2010
Table 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment,
2015—based on late stage development projects evaluated ($ in billions)
Figure 6-4: Global Pharmaceutical Market Forecast by Therapeutic Segment,
2015—based on late stage development projects evaluated
Figure 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment,
2015—Potential Impact from Late-Stage Development
Figure 6-6: Global Pharmaceutical Market Forecast by, 2015—Potential Impact
from Late-Stage Development
CHAPTER SEVEN: BIOPHARMACEUTICAL MARKET
Table 7-1: Top 10 Biotechnology Companies*, 2009 Sales
Table 7-2: Top 10 Biotechnology and Pharmaceutical Products, by 2009
Revenues
Table 7-3: Biotechnology Late Stage Development Projects by Company
Classification—Pharmaceutical vs. Biotechnology--Market Forecast, 2015
Available immediately for Online Download at
http://www.marketresearch.com/product/display.asp?productid=2691449

14. US: 800.298.5699
UK +44.207.256.3920
Int'l: +1.240.747.3093
Fax: 240.747.3004